Evaluating Marinus: Ztalmy’s Growth And Upcoming Trial Insights (NASDAQ:MRNS)

fmajor/E+ via Getty Images Introduction Marinus Pharmaceuticals (NASDAQ:MRNS), focusing on seizure disorders, got FDA approval in 2022 for Ztalmy (ganaxolone) to treat seizures in CDD patients over two. Ganaxolone, affecting GABAA receptors, shows anti-seizure effects. Marinus aims to expand its use and application methods. In my most recent analysis of Marinus, I highlighted their strategic…

Read More